Belite Bio to Participate in the Leerink Partners Global Healthcare Conference

Company Overview - Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs [3] - The company is targeting conditions such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) associated with advanced dry age-related macular degeneration (AMD) [3] Product Development - Belite's lead candidate, Tinlarebant, is an oral therapy designed to reduce toxin accumulation in the eye [3] - Tinlarebant is currently undergoing multiple clinical trials: a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) for adolescent STGD1 subjects, as well as a Phase 3 study (PHOENIX) for subjects with GA [3] Upcoming Events - The executive management team will participate in the Leerink Partners Global Healthcare Conference from March 10-12, 2025, in Miami, FL [1] - A fireside chat hosted by the company is scheduled for March 10, 2025, at 3:00 pm ET [1] - A webcast of the fireside chat will be available on the investor relations section of the Belite Bio website and will be archived for 90 days post-presentation [2]